期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 20, 期 4, 页码 507-534出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543771003657164
关键词
cancer; cardiovascular disease; DPN; ERB-041; ER beta selective agonists; estrogen receptor subtype beta; estrogen replacement therapy; inflammation; MF-101; nonsteroidal estrogens; PPT
Importance of the field: Nonsteroidal estrogens have been known since the 1930s. However, the relatively recent (1996) discovery of estrogen receptor subtype beta (ER beta) suggested a possible paradigm shift away from SERM-like selectivity. Selective ER beta agonism would potentially allow expansion of estrogenic targeting into new indications (discussed herein) currently precluded by the thrombogenic and hyperproliferative effects of nonselective estrogens. Areas covered in this review: ER beta agonist design has been very successful. Pharmacophores for ER beta selective nonsteroidal estrogens are generally diphenolic compounds that achieve an inter-phenolic distance and geometry similar to 17 beta-estradiol with few restraints on the nature of the element linking the phenols (or phenol mimetics). The tremendously chemodiverse ER beta agonist patent literature is reviewed, segregating the agonists into structurally similar compounds based on their interphenolic linking elements. What the reader will gain: A comprehensive understanding of the chemotype landscape of this field and an assessment of its maturation. Take home message: Subtype selective ER beta agonist therapy seems very promising. However, more clinical testing is needed to firmly establish its therapeutic potential. At this point, ER beta is a promising target in search of an indication.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据